Biomarin Pharmaceutical Inc (BMRN) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
Total Assets Chart for Biomarin Pharmaceutical Inc
Biomarin Pharmaceutical Inc (BMRN) total assets for FY2025 were USD 7.6B, a 8.7% change from FY2024. Biomarin Pharmaceutical Inc's total assets grew from USD 31.5M in 1998 to USD 7.6B in 2025 (24000.4% over 27 years). Total assets compound annual growth rate: 5-year CAGR of 5.4%, 10-year CAGR of 7.4%, 20-year CAGR of 20.1%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $10.88B
- Implied Share Price
- $56.22
- Enterprise Value
- $15.37B
- Revenue (TTM)
- $3.41B
- EBITDA
- $645.32M
- Profit Margin
- 2.14%
- Trailing P/E
- 151.95
- Forward P/E
- 9.40
- Price/Book (MRQ)
- 1.90
- Price/Sales (TTM)
- 3.19
- EV/EBITDA
- 39.85
- EV/Revenue
- 4.51
- Dividend Yield
- —
- Book Value
- $32.66
- Free Cash Flow (FY2025)
- $724.96M
- Free Cash Flow Yield
- 6.66%
Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.